Dupilumab for prurigo nodularis: Case series and review of the literature
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.13222
Abstract: Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukinâ4 and interleukinâ13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis… read more here.
Keywords: literature; dupilumab prurigo; treatment; prurigo nodularis ... See more keywords